Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Committee for Medicinal Products for Human Use or CHMP has recommended a marketing authorization for Astellas Pharma's Mycamine, 50mg and 100mg, powder for solution for infusion, intended for the treatment and prophylaxis of Candida infection.
Subscribe to our email newsletter
The active substance of Mycamine is micafungin, an antimycotic for systemic use. The benefits with Mycamine are its clinical and microbiological cure and prophylaxis of Candida infection. The most common side effects are vomiting, nausea and diarrhoea and elevated liver enzymes.